# Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A

> **NCT05281185** · PHASE4 · COMPLETED · sponsor: **Chulalongkorn University** · enrollment: 15 (actual)

## Conditions studied

- Severe Hemophilia A Without Inhibitor

## Interventions

- **DRUG:** Extended half-life FVIII concentrates with PK-guided dosing
- **DRUG:** standard half-life FVIII concentrates with weight-based dosing

## Key facts

- **NCT ID:** NCT05281185
- **Lead sponsor:** Chulalongkorn University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-04-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05281185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05281185, "Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05281185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*